Subscribe Now Subscribe Today
Science Alert
 
Blue
   
Curve Top
Journal of Pharmacology and Toxicology
  Year: 2022 | Volume: 17 | Issue: 2 | Page No.: 50-57
DOI: 10.3923/jpt.2022.50.57
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Immune Response and Antibody-Dependent Mechanism Against Viral Infections: SARS-CoV-2 Vaccine as a Case Study

Abolaji Samson Olagunju , John Oluwafemi Teibo, Olayinka Anthony Adebayo, Opeyemi Abigail Akinfe and Olaide Damilola Olagoke

Abstract:
The immune system is a homeostatic mechanism that defends against a variety of infections. To eradicate viral particles/viruses, the immune system of the host uses several immunological responses (adaptive, innate and complement systems). Furthermore, there are well-equipped sensors in the immune system that bring about precise responses and also identify invading pathogens resulting in eradicating multiple copies of new viruses. The host antiviral antibodies play essential roles in the host response immunologically to viral invasions because they neutralize and diminish the virus's contagion. Conversely, the various antibodies that originally protect the host occasionally help the virus infectivity by enhancing their entry and replication in the target cell. The interaction between virus-antibody immune complexes the Fc and/or complement receptors on some specific host cells type which improves the entry of the virus into the host cells is referred to as antibody-dependent enhancement (ADE). Internalized immune complexes affect the host immunological response, enhancing virus proliferation and worsening illness severity. In the research and development of viral vaccines and immune therapeutics, the risk of ADE induction remains a concern to be illuminated.
PDF Fulltext XML References Citation Report Citation
How to cite this article:

Abolaji Samson Olagunju, John Oluwafemi Teibo, Olayinka Anthony Adebayo, Opeyemi Abigail Akinfe and Olaide Damilola Olagoke, 2022. Immune Response and Antibody-Dependent Mechanism Against Viral Infections: SARS-CoV-2 Vaccine as a Case Study. Journal of Pharmacology and Toxicology, 17: 50-57.

DOI: 10.3923/jpt.2022.50.57

URL: https://scialert.net/abstract/?doi=jpt.2022.50.57

COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 

Curve Bottom